Polymer Solutions for Cardiovascular Devices
In cardiovascular care, where miniaturized, implantable devices must function flawlessly, precision is everything. Pacemakers and other cardiovascular implants require biocompatible, tight-tolerance polymer components that ensure long-term stability and patient safety.
As one of Europe’s largest PEEK producers, we provide advanced polymer manufacturing solutions tailored to the stringent demands of cardiovascular device manufacturing.
Expertise in Cardiovascular Polymer Components
Our specialized polymer manufacturing capabilities meet the unique challenges of cardiovascular devices, delivering micron-level accuracy and biocompatibility in every component.
Injection Molding for PEEK & High-Performance Polymers
- Ideal for implantable medical devices, offering exceptional strength, stability, and biocompatibility
- Expertise in precision molding for pacemakers and cardiovascular implants
Micro-Precision Molding for Small-Scale Components
- Tight-tolerance parts critical for pacemaker housings, connectors, and lead insulation
- Dimensional accuracy at a microscopic scale to ensure seamless integration
Scalable, High-Volume Manufacturing
- Automated, high-efficiency production for cost-effective, consistent quality
- Capabilities to scale from low-volume specialized production to mass manufacturing
Regulatory Compliance & Cleanroom Manufacturing
- ISO-certified cleanrooms ensure sterility and contamination control
- Regulatory guidance to simplify compliance with cardiovascular implant standards
Integrated Manufacturing for Seamless Production
Integrated Manufacturing for Seamless Production
From precision molding to final assembly and sterile packaging, our end-to-end approach ensures:
✔ Sterility and cleanliness for cardiovascular implants
✔ Micron-level accuracy for pacemaker components and other life-sustaining devices
✔ Scalability without compromising on quality or performance
With decades of expertise in medical polymer solutions, we provide the technical precision and production capabilities needed for next-generation cardiovascular therapies.